Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HWI-001
- Development stage
- Preclinical
- Lead developer
- Hanwha Pharma
- Modality
- Small Molecules
01
Overview
HWI-001 is an investigational drug candidate currently in preclinical development by Han Wha Pharma. It is being developed for the treatment of musculoskeletal disorders and peripheral artery diseases (PAD). As a preclinical asset, specific details regarding its chemical structure, molecular target, and mechanism of action have not been publicly disclosed by the developer. The dual focus on musculoskeletal and vascular indications suggests the candidate may target pathways involved in inflammation, pain modulation, or vascular regeneration. HWI-001 represents part of Han Wha Pharma's internal innovation pipeline, which includes several 'HWI' coded assets aimed at addressing unmet medical needs in various therapeutic areas.
Beyond the preview
Go deeper on HWI-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HWI-001.